Vetter Pharma Sustainability Profile
Vetter Pharma, officially known as Vetter Pharma-Fertigung GmbH & Co. KG, is a leading global provider of aseptic filling and packaging services for the pharmaceutical and biotechnology industries. Headquartered in Ravensburg, Germany, the company operates extensively across Europe, North America, and Asia, catering to a diverse clientele. Founded in 1950, Vetter Pharma has achieved significant milestones, including the development of innovative delivery systems and a commitment to high-quality standards. The company specialises in prefilled syringes, vials, and cartridges, distinguished by their precision and reliability. Vetter's strong market position is underscored by its reputation for excellence and a robust portfolio of services that support drug development and commercialisation. With a focus on customer-centric solutions, Vetter Pharma continues to be a trusted partner in the evolving landscape of healthcare.
DitchCarbon Score
How does Vetter Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Vetter Pharma's score of 42 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Vetter Pharma's reported carbon emissions
In 2024, Vetter Pharma reported total carbon emissions of approximately 16,986,000 kg CO2e, with Scope 1 emissions accounting for about 16,044,200 kg CO2e and Scope 3 emissions at approximately 3,778,000 kg CO2e. The Scope 3 emissions included significant contributions from business travel (about 634,960 kg CO2e) and waste generated in operations (approximately 2,891,810 kg CO2e). Comparatively, in 2023, the company recorded about 17,852,000 kg CO2e in total emissions, with Scope 1 emissions at approximately 17,852,000 kg CO2e and Scope 3 emissions at around 3,613,000 kg CO2e. This indicates a reduction in total emissions from 2023 to 2024. Vetter Pharma has set ambitious climate commitments, aiming for a substantial reduction of 58.8% in absolute Scope 1 and 2 emissions by 2034, using 2021 as the base year. This target is currently being validated by the Science Based Targets initiative (SBTi). Additionally, the company is committed to achieving an annual reduction of 4.2% in CO2 emissions from both Scope 1 and Scope 2, starting from 2021 and continuing until 2030. Long-term, Vetter Pharma aims to achieve net zero emissions across all scopes by 2050, reflecting its commitment to sustainable practices within the pharmaceutical industry. The company also plans for 80% of its suppliers, by spend, to have science-based targets by 2029, further enhancing its sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 19,683,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | - |
| Scope 3 | - | 0,000,000 | 0,000,000 | 0,000,000 |
How Carbon Intensive is Vetter Pharma's Industry?
How Carbon Intensive is Vetter Pharma's Location?
Vetter Pharma's Scope 3 Categories Breakdown
Vetter Pharma's Scope 3 emissions, which increased by 5% last year and increased by approximately 32% since 2022, demonstrating supply chain emissions tracking. Their carbon footprint includes supplier sustainability and value chain emissions data across Scope 3 categories, with "Waste Generated in Operations" being the largest emissions source at 77% of Scope 3 emissions.
Top Scope 3 Categories
Vetter Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Vetter Pharma has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Vetter Pharma's sustainability data and climate commitments
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.